TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02944578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin (Curcumin C3 Complex®, prepared by Sabinsa Corporation), a constituent of the spice turmeric, is considered to be a low-toxicity, dietary-derived agent with chemopreventive and therapeutic benefits.~Study participants will be instructed to insert four 500 mg (2000 mg total) curcumin capsules once a week (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants randomized to the placebo arm will insert four 500 mg (2000 mg total) of the placebo (gelatin) capsules once a week (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes.
Study: NCT03995238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Error-augmentation gait training
Description: Split-belt treadmill training to enhance between-limb asymmetry during treadmill walking, which is intended to force compensation and correction of step asymmetry during treadmill walking. The error-augmentation gait training program is delivered in 8 sessions over 4 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Error-correction gait training
Description: Metronome will be set to cue participants to overcorrect between-limb step asymmetry during treadmill walking, through use of asymmetrical metronome tones in a 2:1 ratio. The error-correction gait training program is delivered in 8 sessions over 4 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised walking
Description: An active comparator intervention, in which a supervised treadmill walking program is delivered without attempt to correct step asymmetry. The supervised walking program is delivered in 8 sessions over 4 weeks.
Study: NCT03660046

Intervention type: DRUG
Intervention: Depot medroxyprogesterone acetate (DMPA)
Description: Depot medroxyprogesterone acetate (DMPA) will be dispensed from the Grady Pharmacy Service and will be administered every 12 weeks at the standard dose of 150 mg Intramuscular injection, beginning from week 3 of study enrollment and repeated every 13 weeks

Intervention type: DRUG
Intervention: Etonogestrel implant (Eng-Implant)
Description: A standard Nexplanon rod Implant that is a subdermal implant in the arm. This will be placed at study week 3 by Dr. Haddad or a trained clinician. It contains Etonogestrel 68mg.

Intervention type: DRUG
Intervention: Levonorgestrel IUD (Lng-IUD)
Description: The Levonorgestrel Intrauterine Device (Lng-IUD) (Mirena or copper) will be placed at study week 3 by Dr. Haddad or a trained clinician.
Study: NCT03393221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ER
Description: Emotion regulation content

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SBWC

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBWC
Study: NCT00614796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coach, using a stepcounter with exercise counseling
Description: 5 counseling meetings of 30 min in the first 3 months. In counseling, patients will be stimulated individually to enhance a physically active lifestyle.
Study: NCT00977067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0152
Description: Intravenous escalating dose
Study: NCT00595569

Intervention type: BEHAVIORAL
Intervention: Flexible insulin therapy (FIT)
Description: Flexible insulin therapy (FIT) courses consisting in 7 weekly ambulatory sessions lasting 90 minutes each
Study: NCT02007928

Intervention type: OTHER
Group type: OTHER
Intervention: Rispéridone, aripiprazole, olanzapine
Description: Study:~We propose a prospective, interventional multicenter study.~Method:~Both in and out patients may be included in the study Patients will be recruited over a period of 24 months. They will be followed up for 12 months. Each patient will receive one year of therapeutic monitoring after the introduction of the antipsychotic drug.~The therapeutic monitoring will include clinical, electrocardiographical, and laboratory assessments. These assessments are performed at baseline (before prescribing treatment) and at 1 month (M1), at 3 months (M3), 6 months (M6), 9 months (M9), and at 12 months (M12) after the first prescription of the antipsychotic drug.
Study: NCT02888028

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICD remote monitoring
Description: ICD remote monitoring additionally to regular in-office visits

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Regular in-office visits/FU 1,3,6 and 12 months post implantation of an ICD or post ICD replacement w/o remote FU
Study: NCT01166594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intrableb injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: intrableb BSS injection
Study: NCT03755024

Intervention type: DEVICE
Intervention: ultrasound
Description: The compulsory ultrasound measurements to be obtained at all visits include the following biometrical parameters:~* Biparietal diameter~* Head circumference~* Abdominal circumference~* Femur length~* Humerus length

Intervention type: DEVICE
Intervention: ultrasound
Description: The compulsory ultrasound measurements to be obtained at all visits include the following biometrical parameters:~* Biparietal diameter~* Head circumference~* Abdominal circumference~* Femur length~* Humerus length
Study: NCT01400841

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HAART 300 Annuloplasty Device
Description: Implantation of device for aortic valve repair
Study: NCT03930316

Intervention type: DEVICE
Group type: OTHER
Intervention: NOX T3
Description: portable sleep study device
Study: NCT02726763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Study: NCT02896127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Induction: 4x 150 mg Secukinumab s.c. weekly~Maintenance: 150 mg Secukinumab s.c. monthly~All Subjects received blinded treatment weekly starting at baseline, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4 until Week 16. At Week 16, Group 1 patients continued using secukinumab 150 mg and Group 2 patients started receiving secukinumab 150 mg dosing every four weeks. Treatment was provided open-label from Week 16 onward, as all patients took 150 mg s.c. every 4 weeks; however, subjects, investigators, and site staff remained blinded to initial randomized group assignment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
Study: NCT02753712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone/Formoterol BAI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone/Vilanterol DPI (Relvar Ellipta DPI)
Study: NCT04138927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib disodium
Description: Fostamatinib is supplied in two (2) dosage strengths: 100 mg and 150 mg.
Study: NCT03465293

Intervention type: OTHER
Intervention: Bacterial composition and activity after bowel preparation
Description: Bacterial composition and activity and patient's symptoms will be assessed pre and post bowel preparation taken as part of the preparation to have a pre-planned colonoscopy
Study: NCT02886585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Study: NCT01550939

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Ophthalmic Biometer
Description: One complete biometry examination
Study: NCT04622254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution for injection prepared by reconstitution of powder with percent (%) Sodium Chloride (NaCl).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection prepared by reconstitution of powder with percent (%) Sodium Chloride (NaCl).
Study: NCT01023659

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupropion
Description: bupropion, 150 mg twice daily plus weekly motivational emails for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: varenicline, 1 mg twice daily plus weekly motivational emails for 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: motivational emails
Description: brief motivational emails, sent weekly for 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: motivational emails
Description: brief motivational emails, sent weekly for 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: motivational emails
Description: brief motivational emails, sent weekly for 12 weeks
Study: NCT02744846

Intervention type: DRUG
Intervention: Antibiotics exposure

Intervention type: DRUG
Intervention: Antibiotics exposure
Study: NCT02057757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Participants 1 to 3 years old: 5 mL oral suspension (100 mg NTZ) every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL oral suspension (200 mg NTZ) every 12 hours for 5 days.~Participants 12 years and older: two 300-mg NTZ tablets orally twice daily for 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants 1 to 3 years old: 5 mL placebo oral suspension every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL placebo oral suspension every 12 hours for 5 days.~Participants 12 years and older: two placebo tablets orally twice daily for 5 days.
Study: NCT02575781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR428926
Description: Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR428926
Description: Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR428926
Description: Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
Study: NCT01997086

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous transforaminal endoscopic discectomy (PTED)
Description: Percutaneous transforaminal endoscopic discectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microendoscopic discectomy (MED)
Description: Microendoscopic discectomy
Study: NCT00066196

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI--522
Description: IV administration supplied in 10 mL vials containing 100 mg of MEDI-522 at a concentration of 10 mg/mL.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Integrin + Dacarbazine
Description: supplied in other formulations
Study: NCT03614793

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cooled Radiofrequency Ablation of Medial Branch Nerves versus Facet Joint Injection of Corticosteroid for the Treatment of Lumbar Facet Syndrome
Description: Radio frequency ablation (RFA) is a medical procedure in which heat is generated from high frequency electrical current in order to lesion (burn) nervous tissue.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cooled Radiofrequency Ablation of Medial Branch Nerves versus Facet Joint Injection of Corticosteroid for the Treatment of Lumbar Facet Syndrome
Description: Radio frequency ablation (RFA) is a medical procedure in which heat is generated from high frequency electrical current in order to lesion (burn) nervous tissue.
Study: NCT03541733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mid-gut tubing
Description: mid-gut tubing at different time
Study: NCT02568488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 850 mg orally twice daily for 6 months
Study: NCT01123538

Intervention type: DRUG
Group type: OTHER
Intervention: Progesterone
Description: 200 mg/day oral micronized natural progesterone (e.g. Utrogestan® 100mg) + 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg) during a year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlormadinone acetate
Description: 5 mg/day oral chlormadinone acetate (e.g. Luteran® 5mg)+ 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg)
Study: NCT00895219

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breathing re-training
Description: Breathing re-training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breathing re-training and musculoskeletal techniques
Description: Breathing re-training and musculoskeletal physiotherapy techniques including mobilisation techniques to normalise muscle and joint restrictions, doming of the diaphragm to enhance contraction and relaxation, and rib raising to free restriction in rib cage motion.
Study: NCT00393172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: 5 days per week exercise for 4 months
Study: NCT02538497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Newborn Behavioral Observation (NBO)
Description: The Newborn Behavioral Observation (NBO) is a flexible parental guidance methodology which takes between 20 and 40 minutes to administer. It consists of 18 neurobehavioral observations which give a profile of the infant´s behavioral repertoire along the dimensions: attentional-interactional, autonomic, motor and state organization.~The intervention group will receive 3 NBO consultations: 1) Routine care plus the NBO at the hospital within two days post-delivery; 2) Routine home visit plus the NBO by a public health nurse when the infant is 7-10 days old; and 3) NBO at the well-baby clinic when the infant is about 4 weeks old.
Study: NCT02845037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-453
Description: BIA 5-453 Gelatine capsule for oral administration (1, 10 or 20 mg). Single oral doses of BIA 4-543 2 mg, 10 mg, 20 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg and 1200 mg were administered to subjects in fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-453
Description: BIA 5-453 Gelatine capsule for oral administration (1, 10 or 20 mg). Single oral doses of BIA 4-543 2 mg, 10 mg, 20 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg and 1200 mg were administered to subjects in fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-453
Description: BIA 5-453 Gelatine capsule for oral administration (1, 10 or 20 mg). Single oral doses of BIA 4-543 2 mg, 10 mg, 20 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg and 1200 mg were administered to subjects in fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-453
Description: BIA 5-453 Gelatine capsule for oral administration (1, 10 or 20 mg). Single oral doses of BIA 4-543 2 mg, 10 mg, 20 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg and 1200 mg were administered to subjects in fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-453
Description: BIA 5-453 Gelatine capsule for oral administration (1, 10 or 20 mg). Single oral doses of BIA 4-543 2 mg, 10 mg, 20 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg and 1200 mg were administered to subjects in fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-453
Description: BIA 5-453 Gelatine capsule for oral administration (1, 10 or 20 mg). Single oral doses of BIA 4-543 2 mg, 10 mg, 20 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg and 1200 mg were administered to subjects in fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-453
Description: BIA 5-453 Gelatine capsule for oral administration (1, 10 or 20 mg). Single oral doses of BIA 4-543 2 mg, 10 mg, 20 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg and 1200 mg were administered to subjects in fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-453
Description: BIA 5-453 Gelatine capsule for oral administration (1, 10 or 20 mg). Single oral doses of BIA 4-543 2 mg, 10 mg, 20 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg and 1200 mg were administered to subjects in fasting conditions.
Study: NCT02538497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine care
Description: The control group will receive routine care. Between 7 and 10 days after birth a public health nurse routinely visits the family at home. Six weeks after birth, the mother and the infant visit the well-baby clinic

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Routine care
Description: The control group will receive routine care. Between 7 and 10 days after birth a public health nurse routinely visits the family at home. Six weeks after birth, the mother and the infant visit the well-baby clinic
Study: NCT03162250

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SOC
Description: Anti-staphylococcal SOC antibiotics dosage and duration of therapy will be based on relevant health-authority approved indications and local and national treatment guidelines.
Study: NCT04274933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Tablet; Oral
Study: NCT01862978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nadroparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04485481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-914
Description: Single dose from 0.1mg/kg to TBD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching single dose placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-914
Description: Multiple dose from TBD to TBD
Study: NCT02845037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-453
Description: BIA 5-453 Gelatine capsule for oral administration (1, 10 or 20 mg). Single oral doses of BIA 4-543 2 mg, 10 mg, 20 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg and 1200 mg were administered to subjects in fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Gelatine capsule for oral administration. The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient (API).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Gelatine capsule for oral administration. The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient (API).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Gelatine capsule for oral administration. The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient (API).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Gelatine capsule for oral administration. The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient (API).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Gelatine capsule for oral administration. The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient (API).
Study: NCT04485481

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching multiple dose placebo